Incyte (INCY) investor relations material

Leadership and company transformation

• CEO transition brought renewed focus on underappreciated core business and pipeline, with strong R&D and commercial capabilities highlighted.

• Financial position is robust, with strong revenue growth, cash flow, and a growing balance sheet.

• Growth profile post-2029 is now clearer, with major milestones achieved in the past year.

Commercial performance and product lifecycle

• Jakafi sales grew 7% this quarter, with PV expected to become its largest indication by 2026; sustainable growth anticipated through 2028.

• Jakafi XR, a once-daily formulation, aims for 20% conversion by early 2028, with formulary coverage as a key driver.

• OPZELURA projected to grow at a 10%-15% CAGR, reaching $1.3 billion by 2030, with strong U.S. and international expansion plans.

• International OPZELURA launch for AD in 2026 expected to add $200-$300 million in sales, with Germany as the first EU market.

Pipeline and future growth drivers

• Core business (including MONJUVI, ZYNYZ, and povo) expected to be a $3-$4 billion business, growing at ~20% CAGR.

• MONJUVI frontline DLBCL launch and povo introduction in 2027 are key to maintaining the revenue floor.

• POVO positioned as a multi-cytokine inhibitor for HS, targeting both pre- and post-biologic patients, with pricing between $7,000-$10,000/month.

• OPZELURA and POVO expected to be complementary in HS and vitiligo, leveraging existing sales infrastructure.